Pfizer’s Paxlovid® Likely To Sell ~$24 Billion In 2022; Merck To Break $12 Billion In Same Period With Lagevrio® -- Its Covid-19 Pill.

These are staggeringly vast figures, for a first full year, in any market. The world's governments are ready to buy as much of each treatment as either company can crank out safely.

But going from zero to $24 billion (or $12 billion) in under 12 elapsed months, in a highly regulated manufacturing environment -- is no mean feat.

Not even Keytruda^® (now the world's top selling therapeutic) launched like that -- it took four full years to break the $10 billion barrier.

This also very fairly raises the question of whether the lobbyists should hold the sway they do, over the Senate and House -- as to drug pricing matters. [See this, and this, below.] In any event, here is the latest, from Bloomberg:

. . .Overall sales of Covid pills are expected to hit $32.5 billion this year, up from a previous estimate of $19.5 billion, London-based Airfinity said Friday. Sales of pills from Merck & Co. and Shionogi & Co. are also set to rise as cases increase and earlier treatments are rendered ineffective by new variants. . . .

Onward -- do take care of your mother, now. . . she's the only one we've (collectively) got. Smile. . . .

नमस्ते